IDEXX Laboratories, Inc. $IDXX Shares Acquired by Cresset Asset Management LLC

Cresset Asset Management LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 48.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 3,893 shares of the company’s stock after buying an additional 1,277 shares during the period. Cresset Asset Management LLC’s holdings in IDEXX Laboratories were worth $2,088,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at $29,000. Ameritas Advisory Services LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at $36,000. Elevation Point Wealth Partners LLC acquired a new position in IDEXX Laboratories in the second quarter valued at $36,000. NewSquare Capital LLC increased its stake in IDEXX Laboratories by 87.5% in the second quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after purchasing an additional 35 shares during the last quarter. Finally, WPG Advisers LLC purchased a new position in IDEXX Laboratories during the first quarter worth about $37,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Down 1.0%

Shares of IDXX stock opened at $706.65 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The firm’s 50 day moving average price is $677.46 and its two-hundred day moving average price is $615.21. The stock has a market cap of $56.43 billion, a price-to-earnings ratio of 56.04, a price-to-earnings-growth ratio of 4.26 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The business’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.98% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on IDXX. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, December 1st. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. JPMorgan Chase & Co. lifted their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, UBS Group boosted their price objective on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $763.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.